Kymriah Den europeiske union - norsk - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Libmeldy Den europeiske union - norsk - EMA (European Medicines Agency)

libmeldy

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - andre nervesystemet narkotika - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Carvykti Den europeiske union - norsk - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multippelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Aranesp Den europeiske union - norsk - EMA (European Medicines Agency)

aranesp

amgen europe b.v. - darbepoetin alfa - anemia; cancer; kidney failure, chronic - andre antianemic preparations - behandling av symptomatisk anemi assosiert med kronisk nyresvikt (crf) hos voksne og pediatriske pasienter. behandling av symptomatisk anemi hos voksne pasienter med ikke-myeloide malignitet mottar kjemoterapi.

Lysodren Den europeiske union - norsk - EMA (European Medicines Agency)

lysodren

hra pharma rare diseases - mitotane - binyrebark i binyrebark - antineoplastiske midler - symptomatisk behandling av avansert (ikke-resekterbart, metastatisk eller tilbakefallende) binyrebarkert karsinom. effekten av lysodren på ikke-funksjonelle binyrebark carcinoma er ikke etablert.

Sylvant Den europeiske union - norsk - EMA (European Medicines Agency)

sylvant

recordati netherlands b.v. - siltuximab - giant lymfeknudehyperplasi - immunsuppressive - sylvant er indisert for behandling av voksne pasienter med multisentrisk castlemans sykdom (mcd som er humant immunodefektvirus (hiv) negativt og humant herpesvirus-8 (hhv-8) negativt.

Anatera 100 mg/ ml Norge - norsk - Statens legemiddelverk

anatera 100 mg/ ml

alcon nordic a/s - fluoresceinnatrium - injeksjonsvæske, oppløsning - 100 mg/ ml

Asasantin Retard 200 mg / 25 mg Norge - norsk - Statens legemiddelverk

asasantin retard 200 mg / 25 mg

boehringer ingelheim international gmbh - dipyridamol / acetylsalisylsyre - kapsel med modifisert frisetting, hard - 200 mg / 25 mg

Diprasorin 200 mg / 25 mg Norge - norsk - Statens legemiddelverk

diprasorin 200 mg / 25 mg

orion corporation - espoo - dipyridamol / acetylsalisylsyre - kapsel med modifisert frisetting, hard - 200 mg / 25 mg

Clobex 500 mikrog/ g Norge - norsk - Statens legemiddelverk

clobex 500 mikrog/ g

galderma nordic ab - klobetasolpropionat - sjampo - 500 mikrog/ g